HTG Molecular Diagnostics, Inc.

As of March 31, 2023, HTG Molecular Diagnostics, Inc. carries a market capitalization of 5.98M, placing it among publicly traded companies globally. Its enterprise value stands at 3.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

HTG Molecular Diagnostics, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2023, HTG Molecular Diagnostics, Inc. has 2.21M shares outstanding.

These figures are as of March 31, 2023. The price-to-sales ratio is 0.68, and the price-to-book ratio stands at 12.60.

These figures are as of March 31, 2023. The EV/Sales ratio of 0.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.40M versus a market cap of 5.98M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2023, HTG Molecular Diagnostics, Inc. maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 838.92, indicating elevated leverage, while an interest coverage ratio of -25.61 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2023, HTG Molecular Diagnostics, Inc. posted a negative return on equity (ROE) of -343.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -102.48, reflecting losses generated across the asset base. The company generates approximately 88,775.37 in revenue per employee across its workforce of 70.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.64 indicates how many times HTG Molecular Diagnostics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2023, HTG Molecular Diagnostics, Inc. recorded 12,669.00 in income tax expense. The company reported a pretax loss of -20.14M and -20.15M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 8, 2026, HTG Molecular Diagnostics, Inc.'s stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended March 31, 2023, HTG Molecular Diagnostics, Inc. generated 6.21M in revenue and converted that into -20.15M in net income, yielding earnings per share of -12.87. EBITDA reached -19.10M, while operating income came in at -19.59M.

As of March 31, 2023, HTG Molecular Diagnostics, Inc. holds 6.56M in cash and equivalents against 3.98M in total debt, resulting in a net debt position of 79,097.00. Total book value stands at 474,502.00, with working capital of 2.63M providing operational flexibility.

HTG Molecular Diagnostics, Inc. produced -16.83M in operating cash flow over the twelve months ended March 31, 2023. After subtracting -20,867.00 in capital expenditures, free cash flow totaled -16.85M - equivalent to -10.76 per share.

Over the twelve months ended March 31, 2023, HTG Molecular Diagnostics, Inc. posted a gross margin of 21.69, reflecting its pricing power and cost economics. The operating margin of -315.21 and net profit margin of -324.28 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2023. Free cash flow yield is negative at -398.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -28.92, meaning HTG Molecular Diagnostics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

HTG Molecular Diagnostics, Inc.'s most recent stock split took place on December 21, 2022 with a 12:1 split ratio.

As of March 31, 2023, HTG Molecular Diagnostics, Inc. has an Altman Z-Score of -35.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.